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The statistical power of cross-over trials can be increased by taking “baseline” 
measurements of the outcome variable at the start of each treatment period. Analysis of 
covariance (ANCOVA), rather than analysis of change scores, takes best advantage of 
this.  However, ANCOVA can give biased treatment effect estimates in observational 
studies with true baseline imbalance. Whilst in truth balanced, chance baseline 
imbalance is possible in individual randomised cross-over studies due to their typically 
small sample size. Although such chance imbalance does not cause biased estimation on 
average over repeated trials, this simulation study will aim to confirm the 
appropriateness of ANCOVA when faced with the analysis of data from an individual 
trial in which chance baseline imbalance is clearly apparent. Randomised cross-over 
trials were simulated, varying in sample size and the pattern and strength of correlation 
between repeated measures. Estimates from ANCOVA, change scores, and post-
treatment difference were unbiased on average across each set of simulated datasets. 
ANCOVA and change scores could use baseline information to improve precision, but 
change scores could also reduce precision if baseline measures were uninformative. 
Change scores only were correlated with chance within-subject baseline imbalance. All 
three estimators could be correlated with chance between-subjects imbalance in the first 
period baseline measurements, the strongest associations being with the post-treatment 
difference. Consistent results were obtained from a real data example. In conclusion, 
ANCOVA took best advantage of baseline measures to improve precision, and avoided 





Cross-over trials allow efficient within-subject comparisons of interventions aimed at 
symptom control, so long as the underlying disease severity remains stable over the 
successive periods of treatment and separation of treatment periods is sufficient to avoid 
“carry-over” of an intervention’s effects into the following treatment period [1]. In the 
simplest case of two interventions T and C, and two treatment periods, each trial 
participant receives each treatment in turn in a randomly allocated order. With a 
continuous outcome measured at the end of each treatment period, the most straight-
forward estimate of the treatment effect is obtained as the mean of the within-subject 
differences, and a p-value obtained using the paired t-test. 
Baseline measurements of the outcome measure at the start of each treatment period can 
increase the statistical power of a cross-over trial [1,2]. Analysis of covariance 
(ANCOVA) has long been recommended as taking best advantage of these baseline 
measures, as this method explicitly estimates the association between baseline and post-
treatment measures [1-4]. The alternative, to compare change from baseline between the 
two treatments, implicitly assumes perfect correlation between baseline and post-
treatment measures, and an estimate with poorer precision can result when the 
correlation is in fact quite low [1,3-5]. 
ANCOVA may give biased treatment effect estimates in observational studies, where 
the observed treatment groups differ in case-mix and hence there is a genuine imbalance 
in the average baseline measures [6]. Sample sizes are typically small in cross-over 
studies and, despite random allocation to treatment orders, noticeable between-patient  
imbalance will often be apparent when (for example) first period baseline measures are 
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compared between the two treatments [7,8]. In addition, within-patient differences in 
baseline measures may occur through the play of random measurement error or random 
variation in an individual’s symptom levels over time. The aim here is to investigate 
whether the random allocation of treatments to periods prevents bias in ANCOVA 
estimates even when baseline imbalance is clearly apparent from the data observed in a 
particular trial. In other words, is it sufficient for baselines to be balanced in the long 
run when baselines in a particular trial are obviously not balanced? This question has 
been addressed previously of course, in the context of both parallel group and cross-
over trials [9-11]. The present paper brings a selection of this material together and, 
using a simulation study, adds further justification to the recommendation for the use of 
ANCOVA rather than the comparison of change scores. 
The simulation study will focus on the analysis of individual cross-over trials, rather 
than an algebraic analysis of the long-run properties of the estimates. Factors varied in 
the simulation study will include the sample size, and the inter-correlations between the 
repeated measures of the outcome. The factor levels examined will be in line with cross-
over studies of interventions for asthma and cystic fibrosis with lung function as the 
outcome measure. The ANCOVA and change from baseline methods will be applied to 
the simulated data sets, and the mean effect estimates, standard errors, and correlation 
between baseline imbalance and effect estimates will be examined.  The performance of 
the two statistical methods will also be investigated in an analysis of real data from a 





Notation and data set simulation 
Baseline (XTi, XCi) and post-treatment (YTi, YCi) values were simulated for n individuals i 
(i=1, …, n) in a cross-over study comparing active treatment T with control C. For 
simplicity, it is assumed that systematic bias due to period effects, carry-over, and 
treatment by period interaction has been avoided. The effect of treatment T is 
represented by βT, and the placebo effect of control C as βC. For all simulations the 
treatment effect βT is assumed to be an increase in lung function of 0.1 on the natural 
log scale, and the placebo effect βC is assumed to be zero.  
Factors varied in different simulations were study size (n = 24, 48), and the pattern and 
strength of correlation between repeated measures. The pattern of correlations was 
either an equal correlation between every pair of measurements (an exchangeable 
correlation matrix) or a diminishing correlation with an increasing separation in time 
between a pair of measurements (an autoregressive correlation matrix; see the 
Appendix). The strength of correlation was 0.6 or 0.8 between all pairs of 
measurements in simulations employing the exchangeable correlation matrix, and 
between successive measurements in simulations employing the autoregressive 
correlation matrix before reducing according to a power function (see Appendix).  In an 
additional simulation study active treatment reduced correlations with the post-
treatment measure to 0.6, this being achieved by employing what was otherwise an 
exchangeable correlation matrix with correlation of 0.8 between pairs of measurements. 
A further simulation based on the autoregressive correlation matrix had the correlation 
between successive measurements reduced by the washout period (see Appendix). 
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Ten thousand datasets were simulated for each combination of factor levels considered. 
The four observed values were simulated for each patient as realisations from correlated 
normally distributed variables with, marginally, mean and standard deviation 0.4 using 
the functions presented in the Appendix. All these values are realistic for cross-over 
studies of interventions aimed at improving lung function [5,12,13]. 
 
Statistical methods and measures of performance 
The ANCOVA estimate is the intercept term in a normal errors regression of (YTi  - YCi) 
on (XTi - XCi), this approach being exactly equivalent in this simple context to that 
proposed elsewhere [1,5]. The change scores estimate is the mean of the differences 
between (YTi  - XTi) and (YCi - XCi). The post-treatment only estimate is the mean of 
differences between YTi  and YCi.  
The performance of each statistical measure was measured as the average effect 
estimate, and its standard error estimated empirically as the standard deviation over 
10,000 simulations. In addition, the correlations between within-subject baseline 
imbalance, between-subject period 1 baseline imbalance, and each treatment effect 
estimate over each set of 10,000 simulations were calculated. 
 
Real data example 
Data was made available from a three period, three treatment cross-over study of daily 
rhDNase, alternate day rhDNase and hypertonic saline, the aim being to improve lung 
function in children with cystic fibrosis [12,13]. Treatment periods of twelve weeks 
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were separated by two week washout periods. Data on the primary outcome measure, 
forced expiratory volume in one second (FEV1) was used in the present analysis. The 
two pair-wise comparisons made in the original analysis are repeated here using the 
statistical methods under consideration: hypertonic saline versus daily rhDNase and 
alternate day rhDNase versus daily rhDNase. Log-transformed measures of FEV1 were 
used to allow percentage changes in lung function to be estimated, and that approach is 
adopted in the present investigation.  
 
RESULTS 
Table 1 presents the results of the simulation study employing an exchangeable 
correlation matrix. The means over the 10,000 simulations show each of the three 
methods to give unbiased estimates in the long run. The standard errors indicate that the 
poorest precision is achieved by the change scores, but that there is no clear difference 
between the ANCOVA and post-treatment only estimates in these simulation studies. 
Estimates from the three different measures are inter-correlated, with a correlation in 
each of the different simulation scenarios of around 0.9 between ANCOVA and the 
post-treatment difference, around 0.7 between ANCOVA and change scores, and 
around 0.7 between change scores and the post-treatment difference. The chance 
occurrence of within-subject baseline imbalance between treatments is negatively 
correlated with the change scores estimates, but not with the ANCOVA and post-
treatment only estimates (Table 1). The association is more apparent in the smaller 
studies, and appears to be unrelated to the strength of association between repeated 
measurements. A similar pattern of correlations is apparent between treatment effect 
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estimates and between-subject baseline imbalance in the first period (Table 1), except 
that the correlation between this imbalance and the change scores was greater when the 
correlations between repeated measures were weakened. Very similar results are 
obtained when active treatment reduces the correlation between the post-treatment 
measurement and other measurements. 
Table 2 presents the results of the simulation studies based upon an autoregressive 
correlation matrix. Looking first at the simulations without an extra effect of the 
washout period (first three rows of Table 2) there is no convincing evidence of biased 
estimation, and again the poorest precision in estimation is achieved by change scores, 
with little to choose between ANCOVA and post-treatment only estimates. The 
correlation between the ANCOVA and change score estimates is around 0.8 in these 
simulations, around 0.9 between ANCOVA and post-treatment only estimates, and 
around 0.55 between change scores and post-treatment only estimates. Chance within-
subject baseline imbalance between the two treatments is negatively correlated with 
change score estimates, positively correlated with post-treatment only estimates, but is 
not clearly correlated with ANCOVA estimates in these simulations. The strength of 
correlation with post-treatment only estimates reduces with both increasing sample size 
and with weaker correlations between repeated measures, whilst the strength of 
correlation with change scores reduces with increasing sample size only. In these 
simulations all three sets of estimates correlate with between-subject baseline imbalance 
at the start of the first period, with ANCOVA and post-treatment only estimates being 
positively associated with the imbalance, and change scores being negatively associated 
(Table 2, Figure 1). These correlations are not strongly influenced by the sample size, or 
by the strength of correlation between repeated measures. 
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Results in the lowest two rows of Table 2 arise from simulations based on 
autoregressive correlations between repeated measures, but with the washout period 
causing the correlations between the two treatment periods to be weaker. The average 
observed correlation between two measurements in the same treatment period was 0.80, 
whereas that between pairs of measurement in different treatment periods was 0.51. In 
these simulations use of the baseline measures does improve the precision of treatment 
effect estimates, with the ANCOVA estimates offering a small advantage over change 
scores.  Correlations of the treatment effect estimates with within-subject and between-
subject differences in baseline values were unaffected by the weakening of between-
period correlations during the washout period.  
Table 3 presents the results of the real data example. The expected greater precision of 
the ANCOVA compared to the change score estimates is observed but there was no 
improvement in precision with the use of baseline measures. For the comparison of 
daily and alternate day rhDNase, there was little within-subject difference between the 
pre-treatment measures, and as was consequently expected no important differences in 
the estimates of the treatment effect. There was a larger within-subject difference in pre-
treatment measures for the comparison between rhDNase and hypertonic saline and 
greater variation in the estimates resulting from the different statistical methods. The 
change score estimate was most discrepant from the ANCOVA estimate, suggesting a 
larger advantage of daily rhDNase compared to hypertonic saline. Repeated 
measurements of FEV1 were very highly correlated, being around 0.9 for successive 
measures to around 0.85 for measurements taken some time apart. Table 4 gives the full 
correlation matrix which could be considered to fall part way between an exchangeable 





In the long-run all three statistical methods provided unbiased estimates of the true 
treatment effect in the simulation studies considered. The expected extra efficiency with 
the use of baseline measures was only clearly observed in simulations where the 
washout period reduced the strength of correlation between measures taken in different 
treatment periods, with ANCOVA appearing best able to capitalise on that extra 
efficiency. Across the range of simulations in the present investigation, ANCOVA was 
found least likely affected by chance baseline imbalance between treatments, a marked 
correlation with between-subject imbalance in first period baselines only being apparent 
in simulations based on autoregressive correlation between repeated measurements. 
Even in that situation, the simple difference in post-treatment measurements was more 
strongly correlated with that between-subject imbalance. In the real data example 
improved efficiency with the use of baseline measures was not apparent, with their use 
in change scores impacting negatively to give poorer precision. The effect of baseline 
imbalance was consistent with the simulation study results, with noticeable differences 
in the resulting treatment effect estimates only for the comparison with a moderate 
within-subject imbalance in the baseline measures. 
An improvement in treatment effect estimate precision was not apparent with the use of 
baseline measurements in the real data example, and only in those simulations where 
the washout period weakened the correlations between measurements taken in different 
treatment periods. Seeing “in the flesh” the limited the circumstances in which 
collecting extra information improved precision does cause surprise, even though this 
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pattern of results was predictable. Only when the correlation between measurements 
taken in the same treatment period exceeds that between a pair of measurements taken 
in different treatment periods do baseline measurements bring extra precision to a cross-
over study [1,2]. This is not the case for simulations generated using an exchangeable 
correlation matrix, and is only clearly apparent in the simulations generated using the 
autoregressive correlation matrix once the washout period reduces the correlation 
between successive measurements. Hence baseline measurements may be most useful in 
randomised controlled trials requiring a long washout period, in these circumstances 
contributing to the reduction in error variation which the within-subject difference in 
distant post-treatment measurements may be less able to do. Such an effect was not 
clearly apparent in the real data example, where twelve week long treatment periods 
were separated by relatively short two week long washout periods. 
The differing results with the different methods applied to the comparison of daily 
rhDNase and hypertonic saline in the real data example can be understood from the 
well-known relationships between the methods [3,6,11].  Considering our 
implementation of the ANCOVA method: 
(YTi  - YCi) = βT + γ(XTi - XCi)        (1) 
So in the comparison of daily rhDNase and hypertonic saline (XTi - XCi) was negative as 
the hypertonic saline group had better average lung function at baseline. That fact is 
ignored by the post-treatment only analysis, with γ set to zero, and with highly 
correlated measurements the estimated advantage of daily rhDNase βT was attenuated 
by the perseverance of the chance baseline difference into the post-treatment period. 
With the comparison of change scores, γ is set to 1 and βT was estimated as the 
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difference in post-treatment measures, inflated to compensate for the whole 
disadvantage for treatment T at baseline. For ANCOVA γ is estimated, in practical 
circumstances as a value between 0 and 1 reflecting the strength of association between 
baseline and post-treatment measures, and βT was inflated to account for that part of the 
baseline disadvantage for treatment T which carried over to post-treatment. So with no 
allowance for the baseline disadvantage for daily rhDNase, the post-treatment only 
estimate of βT was the most modest, with partial allowance for that disadvantage the 
ANCOVA estimate was greater, and with complete, perhaps over-compensation for the 
disadvantage, the change scores estimate was the highest by some way.  
With cross-over studies having relatively modest sample sizes, random allocation still 
allows a high chance of noticeable between-subject imbalance in the first baseline 
measurement, and within-subject imbalance between the pairs of baseline 
measurements. Within-subject imbalance in baseline measures is captured as part of the 
change scores and ANCOVA approaches, but the change scores method is based on the 
whole of the baseline difference feeding through to the post-treatment measurements 
(equation 1 above), and so will usually over-correct and give biased treatment effect 
estimates. Between-subject imbalance in the first period baseline measurement is not 
directly measured by any of the three statistical methods considered here. Consequently, 
in the present simulations based on autoregressive correlations between repeated 
measures, the post-treatment difference demonstrates the full effect of this baseline 
imbalance, which is under-corrected by the ANCOVA approach and over-corrected by 
the analysis of change scores (see Figure 1). Overall, the ANCOVA method gave biased 
estimates in the most restricted set of circumstances, so providing further justification to 
the use of this method. Change scores were correlated with within-subject and between-
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subject imbalance in all circumstances covered by the simulation study, whilst the post-
treatment difference showed a similar pattern to ANCOVA but with a stronger 
association with between-subject imbalance when repeated measures were generated 
using an autoregressive correlation structure. 
In conclusion, the long-standing recommendation for the use of ANCOVA, rather than 
change scores, in the analysis of cross-over studies with baseline measurements is 
supported by the findings of the present study. The method will take best advantage of 
any further information in baseline measurements to improve precision of estimation, 
but will not reduce that precision when the baselines are uninformative. Furthermore the 
present study shows ANCOVA as being the most likely method to avoid bias when 
there is chance within-subject or between-subject imbalance in the baseline measures. 
The practical consequence of these findings is that the ANCOVA method can safely be 
pre-specified in the statistical protocols of planned cross-over studies, as it was for the 
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APPENDIX: Simulation methods  
Exchangeable correlation matrix 
These simulations are based on an exchangeable correlation matrix to describe the 


























where successive rows and columns correspond to the successive measurements. Box 
A1 gives the functions used in the simulation of values for an individual i, where rand0, 
rand1, rand2, rand3 and rand4 are five randomly generated values from a standard 
normal variable. X are simulated baseline measurements, Y are simulated outcome 
measurements, C denotes the control group and T the treatment group. Here ρ is the 
square root of the resulting correlation between pairs of simulated measures, values of 
0.894427 (square root of 0.8) and 0.7746 (square root of 0.6) being employed in this 
study. The true mean and standard deviation of the simulated measurements are denoted 
as μ and σ respectively, 0.4 being used for both in all of these simulations. The true 
treatment effect is denoted as trt and is 0.1 in all simulations. In some simulations the 
treatment reduces the correlation between baseline and post-treatment measurements, 
with π changed from 1 to 0.8 to introduce this aspect. 
 
Autoregressive correlation matrix 
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These simulations are based on a first order autoregressive correlation matrix to 

























 where successive rows and columns correspond to the successive measurements. Box 
A2 describes the functions used in the simulation of values for an individual i, where 
rand1, rand2, rand3 and rand4 are four randomly generated values from a standard 
normal variable; and m1, m2, m3, and m4 are intermediate calculations which introduce 
the autoregressive correlation across the sequence of measurements.  X are simulated 
baseline measurements, Y are simulated outcome measurements, C denotes the control 
group and T the treatment group. Here ρ is the correlation between one measure and that 
immediately following it, the correlation between pairs of measurements being less if 
they are further apart in the sequence of measurements. Taking this a step further, 
additional simulations were conducted with the washout period weakening the 

























The true mean and standard deviation are denoted as μ and σ respectively with both 
taking the value of 0.4 in all simulations. The true treatment effect is denoted trt and is 




Figure 1. Effect estimates from the three methods plotted against the between-subject 
difference in period one baseline measures for 10,000 simulated datasets generated 





Table 1. Results of the simulation study, based on an exchangeable correlation matrix. For each combination of factor levels 10,000 data sets 
















ANCOVA 0.100 (0.052) -0.007 +0.005 MODERATE STUDY 
n=24, correlation=0.8, 
SD(within-subject baseline diff.) = 0.255 
Change scores 0.101 (0.072) -0.150 -0.221 
Post-treatment only 0.100 (0.051) -0.008 +0.004 
      
ANCOVA 0.100 (0.037) -0.008 -0.002 LARGER STUDY 
n=48, correlation=0.8, 
SD(within-subject baseline diff.) = 0.250 
Change scores 0.099 (0.051) -0.098 -0.228 
Post-treatment only 0.100 (0.036) -0.008 -0.004 
      
ANCOVA 0.100 (0.052) -0.008 -0.007 WEAKER CORRELATION 
n=48, correlation=0.6, 
SD(within-subject baseline diff.) = 0.353 
Change scores 0.100 (0.073) -0.098 -0.322 
Post-treatment only 0.100 (0.051) -0.008 -0.010 
      
ANCOVA 0.100 (0.049) -0.009 -0.008 TREATMENT REDUCES CORRELATION 
n=48, correlation=0.8, reduced to 0.64, 
SD(within-subject baseline diff.) = 0.250 
Change scores 0.099 (0.061) -0.085 -0.196 
Post-treatment only 0.100 (0.049) -0.010 -0.010 
 
Table 2. Results of the simulation study, based on an autoregressive correlation matrix. For each combination of factor levels 10,000 data sets 
















ANCOVA 0.100 (0.064) -0.004 +0.167 MODERATE SIZE STUDY 
n=24, correlation=0.8j, 
SD(within-subject baseline diff.) = 0.345 
Change scores 0.100 (0.075) -0.123 -0.089 
Post-treatment only 0.100 (0.068) +0.083 +0.331 
ANCOVA 0.099 (0.045) -0.016 +0.168 LARGER SIZE STUDY 
n=48, correlation=0.8j, 
SD(within-subject baseline diff.) = 0.340 
Change scores 0.098 (0.053) -0.100 -0.095 
Post-treatment only 0.099 (0.049) +0.047 +0.328 
ANCOVA 0.098 (0.063) -0.017 +0.160 WEAKER CORRELATION 
n=48, correlation=0.6j, 
SD(within-subject baseline diff.) = 0.453 
Change scores 0.098 (0.077) -0.103 -0.206 
Post-treatment only 0.098 (0.065) +0.028 +0.324 
ANCOVA 0.100 (0.067) -0.005 +0.125 WASHOUT WEAKENS CORRELATION 
n=24, correlation=0.8j, 
SD(within-subject baseline diff.) = 0.401 
Change scores 0.100 (0.075) -0.106 -0.116 
Post-treatment only 0.100 (0.080) +0.117 +0.388 
ANCOVA 0.099 (0.047) -0.015 +0.124 WASHOUT WEAKENS CORRELATION 
n=48, correlation=0.8j, 
SD(within-subject baseline diff.) = 0.395 
Change scores 0.098 (0.053) -0.084 -0.123 
Post-treatment only 0.099 (0.057) +0.071 +0.385 
 
 





































        
ANCOVA 0.0199 (0.0326) 0.546  0.0744 (0.0291) 0.015 
Change scores 0.0047 (0.0415) 0.911  0.1283 (0.0378) 0.002 
Post-treatment only 0.0218 (0.0323) 0.503  0.0595 (0.0282) 0.041 
        
 
 
Table 4. Correlation matrix of observed associations between repeated measures (log scale) in the real data example, a three period cross-over 
study. 
Measurement 1 2 3 4 5 6 
1 1      
2 0.92 1     
3 0.94 0.93 1    
4 0.85 0.89 0.83 1   
5 0.88 0.89 0.85 0.84 1  








Function used to simulate the measure from the randomly generated values 
XCi ((ρ X rand0 + (1 – ρ2)0.5 X rand1) X σ) + μ 
YCi ((ρ X rand0 + (1 – ρ2)0.5 X rand2) X σ) + μ 
XTi, ((ρ X rand0 + (1 – ρ2)0.5 X rand3) X σ) + μ 









Functions used to simulate the measure from the randomly generated values 
m1 rand1 
m2 (ρ X m1 + (1 – ρ2)0.5 X rand2)  
m3 (ρ X m2 + (1 – ρ2)0.5 X rand3)  
m4 (ρ X m3 + (1 – ρ2)0.5 X rand4)  
Allocated to control followed by treatment: 
XCi (m1 X σ) + μ 
YCi (m2 X σ) + μ 
XTi, (m3 X σ) + μ 
YTi (m4 X σ) + μ +trt 
Allocated to treatment followed by control: 
XCi (m3 X σ) + μ 
YCi (m4 X σ) + μ 
XTi, (m1 X σ) + μ 
YTi (m2 X σ) + μ +trt 
 
